Information for you
On this page, we highlight information of partcular relevance for media, including news, events and featured information for journalists with a professional interest in the development and availability of medicines in the European Union.
For more information and details relevant for media, see our News & events section.
For enquiries from media, please contact the EMA press office.
Human medicines highlights for 2016
EMA has released an overview of its key recommendations in 2016 on the authorisation of new medicines. EMA recommended 81 medicines for marketing authorisation. This includes recommendations for 27 new active substances.
Search for all press releases, news items and other media materials.
All about medicines
Search for information on medicines and browse the European database of suspected adverse drug reaction reports.
Find out more about EMA's scientific committees and working parties
Funding, statistics and key operating information
News for media
EMA publishes report with data collected between 2006 and June 2016 ... Read more
CVMP opinions on veterinary medicinal products ... Read more
Two ongoing safety reviews discussed at the January Pharmacovigilance Risk Assessment Committee (PRAC). ... Read more
EMA updates industry guidance on submission of clinical data for publication ... Read more
EMA closed from 18:30 on Thursday 22 December until 7:30 on Tuesday 3 January 2017 ... Read more
- See all News for media
Events of interest
This SME info day provides an overview on the key features and objectives of the new clinical trial regulation. It also covers the future clinical trial authorisation process, the functionalities of the EU CT portal and database, transparency aspects of the new regulation and safety reporting requirements. The event is for companies that have been assigned SME status by the EMA and representatives of stakeholder organisations. ... Read more
30/01/2017 - 31/01/2017
The aim of the EMA and the ACCELERATE platform's workshop is to review unmet therapeutic needs of children with certain types of cancer and opportunities for targeted paediatric development of innovative anti-cancer medicines. Cancers that are addressed include soft tissue and lymphoid and embryonal neoplasms such as inflammatory myofibroblastic tumour, rhabdomyosarcoma, anaplastic large cell lymphoma and neuroblastoma. Important biological aberrations such as of the anaplastic lymphoma kinase (ALK) occur across these diverse cancers, albeit in small numbers of patients, and represent challenges to address the therapeutic needs of affect paediatric patients. The workshop convenes stakeholders from patient organisations, academia, pharmaceutical industry and regulators. ... Read more
This webinar aims to showcase to pharmaceutical companies the benefits of working with the European Network for Paediatric Research at EMA (Enpr-EMA) and the clinical research networks it represents in the development of medicines for children. The speakers include the Enpr-EMA chair, Mark Turner, and co-chair, Irmgard Eichler. They will outline the role of European Medicines Agency in this network and the practical support Enpr-EMA can offer to developers of paediatric medicines. Further details and information on how to connect is included in the agenda on this page under the 'Documents' tab. ... Read more
16/03/2017 - 17/03/2017
The European Medicines Agency veterinary medicines info day, organised in collaboration with International Federation for Animal Health Europe (IFAH-Europe), provides first-hand information on the latest developments in the scientific review, regulation and marketing authorisation procedure in the field of veterinary medicine regulation. For the first time, this year, European Medicines Agency (EMA) will have dedicated information points on esubmissions, veterinary application submissions and veterinary medicines innovation. ... Read more
The European Union-United States strategic bilateral meeting discussed the future of paediatric medicines, the intensification of collaboration, increasing convergence and identifying future challenges. ... Read more
- See all Events of interest